Initial vancomycin dosing in pediatric oncology and stem cell transplant patients

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 1, 2009, Pages 3-7

  Piro, Christina C ^a   Crossno, Christine L ^a   Collier, Anderson ^b   Ho, Richard ^b   Koyama, Tatsuki ^c   Frangoul, Haydar ^b,d  

^a Department of Pharmacy ^*  (United States)

^b 397 PRB   (United States)

^c MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Pediatric oncology; Pediatric stem cell transplant; Vancomycin dosing

Indexed keywords

ACICLOVIR; CARBOPLATIN; CISPLATIN; CYCLOSPORIN; FUROSEMIDE; GENTAMICIN; METHOTREXATE; TACROLIMUS; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; BACTEREMIA; LEUKEMIA; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; LEUKEMIA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 59449085779     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818b3520     Document Type: Article

References (14)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
2. Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis. 2005;40(suppl 4): S253-S256.
3. Kline MW, Mason EO Jr. Methicillin-resistant Staphylococcus aureus: pediatric perspective. Pediatr Clin North Am. 1988;35: 613-624.
4. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr. 1980;96:119-126.
5. Spears RL, Koch R. The use of vancomycin in pediatrics. Antibiot Annu. 1959;7:798-803.
6. Krivoy N, Peleg S, Postovsky S, et al. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol. 1998;15:333-338.
7. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995;15: 85-91.
8. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34:571-590.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
10. Potts AL, Barr FE, Gregory DF, et al. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics. 2004;113(1 Pt 1):59-63.
11. Lehmann CU, Kim GR. Computerized provider order entry and patient safety. Pediatr Clin North Am. 2006;53: 1169-1184.
12. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med. 2003;163:1409-1416.
13. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995; 14:667-673.
14. Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J. 1994;13:969-974.